{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:27:13Z","timestamp":1772742433443,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Herein the quantitative synthesis of eight new mono- and dianionic Organic Salts and Ionic Liquids (OSILs) from alendronic acid (ALN) is reported by following two distinct sustainable and straightforward methodologies, according to the type of cation. The prepared ALN-OSILs were characterized by spectroscopic techniques and their solubility in water and biological fluids was determined. An evaluation of the toxicity towards human healthy cells and also human breast, lung and bone (osteosarcoma) cell lines was performed. Globally, it was observed that the monoanionic OSILs showed lower toxicity than the corresponding dianionic structures to all cell types. The highest cytotoxic effect was observed in OSILs containing a [C2OHMIM] cation, in particular [C2OHMIM][ALN]. The latter showed an improvement in IC50 values of ca. three orders of magnitude for the lung and bone cancer cell lines as well as fibroblasts in comparison with ALN. The development of OSILs with high cytotoxicity effect towards the tested cancer cell types, and containing an anti-resorbing molecule such as ALN may represent a promising strategy for the development of new pharmacological tools to be used in those pathological conditions.<\/jats:p>","DOI":"10.3390\/pharmaceutics12030293","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T13:04:04Z","timestamp":1585055044000},"page":"293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma"],"prefix":"10.3390","volume":"12","author":[{"given":"S\u00f3nia","family":"Teixeira","sequence":"first","affiliation":[{"name":"Faculdade de Medicina Dent\u00e1ria, U. Porto, Rua Dr. Manuel Pereira da Silva, 4200-393 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8973-1595","authenticated-orcid":false,"given":"Miguel M.","family":"Santos","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Departamento de Qu\u00edmica, Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-9574","authenticated-orcid":false,"given":"Maria H.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Dent\u00e1ria, U. Porto, Rua Dr. Manuel Pereira da Silva, 4200-393 Porto, Portugal"},{"name":"UCIBIO-REQUIMTE, Departamento de Qu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, 4169-007 Porto, Portugal"}]},{"given":"Jo\u00e3o","family":"Costa-Rodrigues","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Dent\u00e1ria, U. Porto, Rua Dr. Manuel Pereira da Silva, 4200-393 Porto, Portugal"},{"name":"ESS\u2014Escola Superior de Sa\u00fade, Instituto Polit\u00e9cnico do Porto, R. Dr. Ant\u00f3nio Bernardino de Almeida 400, 4200-072 Porto, Portugal"},{"name":"Instituto Polit\u00e9cnico de Viana do Castelo, Escola Superior de Sa\u00fade, Rua D. Mois\u00e9s Alves Pinho 190, 4900-314 Viana do Castelo, Portugal"}]},{"given":"Lu\u00eds C.","family":"Branco","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Departamento de Qu\u00edmica, Faculdade de Ci\u00eancias e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0968-0896(96)00042-9","article-title":"New drugs\u2014Reports of new drugs recently approved by the FDA: Alendronate","volume":"4","author":"Shinkai","year":"1996","journal-title":"Bioorg. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejps.2012.04.002","article-title":"Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system","volume":"46","author":"Han","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X100276","article-title":"Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis","volume":"22","author":"Iwamoto","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(15)61163-1","article-title":"Bisphosphonates, bone, and breast cancer recurrence","volume":"386","author":"Brufsky","year":"2015","journal-title":"Lancet"},{"key":"ref_5","first-page":"8","article-title":"The Use of Adjuvant Bisphosphonates in the Treatment of Early-Stage Breast Cancer","volume":"12","author":"Mathew","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_6","first-page":"1231","article-title":"Increased osteoclast activity is associated with aggressiveness of osteosarcoma","volume":"33","author":"Avnet","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1039\/b706677p","article-title":"The third evolution of ionic liquids: Active pharmaceutical ingredients","volume":"31","author":"Hough","year":"2007","journal-title":"New J. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1021\/acs.chemrev.6b00562","article-title":"Biological Activity of Ionic Liquids and Their Application in Pharmaceutics and Medicine","volume":"117","author":"Egorova","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cmdc.201100082","article-title":"Ionic Liquids as Active Pharmaceutical Ingredients","volume":"6","author":"Ferraz","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1146\/annurev-chembioeng-060713-040024","article-title":"Ionic Liquids in Pharmaceutical Applications","volume":"5","author":"Marrucho","year":"2014","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1039\/C4CC02021A","article-title":"Ionic liquids for energy, materials, and medicine","volume":"50","author":"Smiglak","year":"2014","journal-title":"Chem. Comm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/528188a","article-title":"Chemistry: Develop ionic liquid drugs","volume":"528","author":"Shamshina","year":"2015","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1039\/c3md20359j","article-title":"Prodrug ionic liquids: Functionalizing neutral active pharmaceutical ingredients to take advantage of the ionic liquid form","volume":"4","author":"Cojocaru","year":"2013","journal-title":"MedChemComm"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1039\/c2ce25842k","article-title":"Polymorphism in an API ionic liquid: Ethambutol dibenzoate trimorphs","volume":"14","author":"Cherukuvada","year":"2012","journal-title":"CrystEngComm"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.201900040","article-title":"Ionic Liquids and Salts from Ibuprofen as Promising Innovative Formulations of an Old Drug","volume":"14","author":"Santos","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1039\/C7NJ01398A","article-title":"Highly water soluble room temperature superionic liquids of APIs","volume":"41","author":"Carrera","year":"2017","journal-title":"New J. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1039\/c2md00269h","article-title":"Development of Novel Ionic Liquids-APIs based on Ampicillin derivatives","volume":"3","author":"Ferraz","year":"2012","journal-title":"Med. Chem. Comm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijpharm.2013.08.010","article-title":"Evaluation of solubility and partition properties of ampicillin-based ionic liquids","volume":"456","author":"Florindo","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1039\/C3RA44286A","article-title":"Antibacterial activity of Ionic Liquids based on ampicillin against resistant bacteria","volume":"4","author":"Ferraz","year":"2014","journal-title":"RSC Adv."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ferraz, R., Silva, D., Dias, A.R., Dias, V., Santos, M.M., Pinheiro, L., Prud\u00eancio, C., Noronha, J.P., Petrovski, Z., and Branco, L.C. (2020). Synthesis and Antibacterial Activity of Ionic Liquids and Organic Salts based on Penicillin G and Amoxicillin hydrolysate derivatives against Resistant Bacteria. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030221"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2014.04.034","article-title":"Novel organic salts based on fluoroquinolone drugs: Synthesis, bioavailability and toxicological profiles","volume":"469","author":"Florindo","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cmdc.201900397","article-title":"A Novel Approach for Bisphosphonates: Ionic Liquids and Organic Salts from Zoledronic Acid","volume":"14","author":"Teixeira","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1039\/b914284n","article-title":"Toxicological evaluation on human colon carcinoma cell line (CaCo-2) of ionic liquids based on imidazolium, guanidinium, ammonium, phosphonium, pyridinium and pyrrolidinium cations","volume":"11","author":"Frade","year":"2009","journal-title":"Green Chem."},{"key":"ref_24","unstructured":"(2020, January 05). NIST Chemistry Web Book, Available online: http:\/\/webbook.nist.gov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111155","DOI":"10.1016\/j.molliq.2019.111155","article-title":"Surface active fatty acid ILs: Influence of the hydrophobic tail and\/or the imidazolium hydroxyl functionalization on aggregates formation","volume":"289","author":"Mezzetta","year":"2019","journal-title":"J. Mol. Liq."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4172\/1948-593X.1000035","article-title":"31P-NMR and Differential Scanning Calorimetry Studies for Determining Vesicle\u2019s Drug Physical State and Fraction in Alendronate Liposomes","volume":"2","author":"Afergan","year":"2010","journal-title":"J. Bioanal. Biomed."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kan, C., Vargas, G., Pape, F.L., and Cl\u00e9zardin, P. (2016). Cancer Cell Colonisation in the Bone Microenvironment. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101674"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Shemanko, C.S., Cong, Y., and Forsyth, A. (2016). What Is Breast in the Bone?. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101764"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/jcb.23439","article-title":"Variability of the paracrine-induced osteoclastogenesis by human breast cancer cell lines","volume":"113","author":"Moniz","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1002\/jcb.23295","article-title":"Reciprocal osteoblastic and osteoclastic modulation in co-cultured MG63 osteosar-coma cells and human osteoclast precursors","volume":"112","author":"Fernandes","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10585-011-9387-7","article-title":"Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: Is RANKL\/RANK signaling really important?","volume":"28","author":"Teixeira","year":"2011","journal-title":"Clin. Exp. Metastas."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/3\/293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:11:05Z","timestamp":1760173865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/3\/293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["pharmaceutics12030293"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12030293","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]}}}